http://www.themarketfinancial.com/new-pain-treatment-triumphs-morphine-otcnphc/489?utm_source=rss&utm_medium=rss&utm_campaign=new-pain-treatment-triumphs-morphine-otcnphc Taking the Risk out of Risk Sat, 11 Feb 2012 01:39:37 +0000 hourly 1 http://wordpress.org/?v= http://www.themarketfinancial.com/new-pain-treatment-triumphs-morphine-otcnphc/489/comment-page-1#comment-161937 Daisy Fox Mon, 23 Jan 2012 11:49:56 +0000 http://www.stockshaven.com/?p=489#comment-161937 What you mention is a fact, but there are recent reports that it must be fixed. It implies not only that many people will resist correcting their factual objectives. What you mention is a fact, but there are recent reports that it must be fixed. It implies not only that many people will resist correcting their factual objectives.

]]> http://www.themarketfinancial.com/new-pain-treatment-triumphs-morphine-otcnphc/489/comment-page-1#comment-768 Ron Wed, 14 Oct 2009 03:11:55 +0000 http://www.stockshaven.com/?p=489#comment-768 Cobroxin has a strong potential to be a blockbuster med. Even pain specialists, which are becoming fewer by the day, are often reluctant to give opiate meds to their patients. the patients must come back monthly and go through a number of therapies as well. this cost a lot and if the person doesn't have insurance, well, tough luck. With Cobroxin, the issue of doctor prescriptions is gone, the issue of addiction is gone, the issue of cost is gone. Even family doctors will recomment this to patients whit chronic pain and there will be ever increasing numbers of them as we age. It is now available on line ans soon in stores. If it works as stated, this will sell as much as they can make. Cobroxin has a strong potential to be a blockbuster med. Even pain specialists, which are becoming fewer by the day, are often reluctant to give opiate meds to their patients. the patients must come back monthly and go through a number of therapies as well. this cost a lot and if the person doesn’t have insurance, well, tough luck.
With Cobroxin, the issue of doctor prescriptions is gone, the issue of addiction is gone, the issue of cost is gone. Even family doctors will recomment this to patients whit chronic pain and there will be ever increasing numbers of them as we age. It is now available on line ans soon in stores.
If it works as stated, this will sell as much as they can make.

]]> http://www.themarketfinancial.com/new-pain-treatment-triumphs-morphine-otcnphc/489/comment-page-1#comment-767 sarath Fri, 11 Sep 2009 08:04:22 +0000 http://www.stockshaven.com/?p=489#comment-767 when will theaudio conference comeup?. Thanks for the info when will theaudio conference comeup?. Thanks for the info

]]> http://www.themarketfinancial.com/new-pain-treatment-triumphs-morphine-otcnphc/489/comment-page-1#comment-766 Buy New Pain Treatment Triumphs Morphine (OTC:NPHC) - StockRants Stock Market Forum Fri, 11 Sep 2009 06:04:12 +0000 http://www.stockshaven.com/?p=489#comment-766 [...] New Pain Treatment Triumphs Morphine (OTC:NPHC) Nutra Pharma Corp. (Public, OTC:NPHC) Step aside Morphine, the new king of chronic pain treatment has entered the building. With Nutra Pharma’s stock rising nearly 2300% year-to-date, its time we see what all the commotion is about. StocksHaven Investments takes a closer look at Nutra Pharma Corp., which believes will begin generating significant revenues within the next 12 months. The company has recently made waves throughout the biotech space with their recent “Best New Product” award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, and was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. Winning this was no easy task, as a handful of well known companies attended the conference. The company is also developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS) through their wholly owned subsidiary, ReceptoPharm Inc. With billions of dollars in potential target markets, Nutra Pharma is one company which is ready to take the biopharmaceuticals sector by storm. About Nutra Pharma Corp. is a development-stage biopharmaceutical company engaged in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. The Company’s wholly owned subsidiary, ReceptoPharm, Inc. (Recepto Pharm) is a development stage biopharmaceutical company, which is engaged in developing technologies to treat the neurological diseases: multiple sclerosis; adrenomyeloneuropathy; amyotrophic lateral sclerosis; myasthenia gravis; and to treat the viral diseases, human immunodeficiency virus (HIV) and hepatitis-C. The Company’s other wholly owned subsidiary Designer Diagnostics, Inc. (Designer Diagnostics) is engaged in marketing diagnostic test kits that are used for the rapid identification of infectious human diseases, such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Midterm goal Nutra Pharma Corp’s midterm strategy for the past three years has been to license Nutra Pharma Corp’s AMN, MS and HIV technologies in Nutra Pharma Corp’s attempt to bring these technologies to market within 5 years. Should Nutra Pharma Corp. obtain adequate financing, Nutra Pharma Corp’s midterm strategy remains the same— to accomplish these midterm goals in the next two years of that 5 year period. Long-term goal Nutra Pharma Corp’s long-term goal is the use of drugs developed by ReceptoPharm and future affiliates in the field of neurological diseases, infectious diseases and autoimmune disorders. Due to Nutra Pharma Corp’s limited financial and operational resources, this goal will require Nutra Pharma Corp. to establish strategic partners or alliances with pharmaceutical companies, academic institutions, biotechnology companies, and clinical diagnostic laboratories, which will: (a) complement Nutra Pharma Corp’s research and development efforts; (b) reduce the risks associated with undertaking the entire process of drug development and marketing; and (c) generate licensing based revenue streams. Read full article at New Pain Treatment Triumphs Morphine (OTC:NPHC) | [...] [...] New Pain Treatment Triumphs Morphine (OTC:NPHC) Nutra Pharma Corp. (Public, OTC:NPHC) Step aside Morphine, the new king of chronic pain treatment has entered the building. With Nutra Pharma’s stock rising nearly 2300% year-to-date, its time we see what all the commotion is about. StocksHaven Investments takes a closer look at Nutra Pharma Corp., which believes will begin generating significant revenues within the next 12 months. The company has recently made waves throughout the biotech space with their recent “Best New Product” award winning drug, Cobroxin. The product is the first clinically proven treatment for stage 2 (moderate to severe) chronic pain, and was awarded the honour at the Efficient Collaborative Retail Marketing (ECRM) Conference in Miami, Florida. Winning this was no easy task, as a handful of well known companies attended the conference. The company is also developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS) through their wholly owned subsidiary, ReceptoPharm Inc. With billions of dollars in potential target markets, Nutra Pharma is one company which is ready to take the biopharmaceuticals sector by storm. About Nutra Pharma Corp. is a development-stage biopharmaceutical company engaged in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. The Company’s wholly owned subsidiary, ReceptoPharm, Inc. (Recepto Pharm) is a development stage biopharmaceutical company, which is engaged in developing technologies to treat the neurological diseases: multiple sclerosis; adrenomyeloneuropathy; amyotrophic lateral sclerosis; myasthenia gravis; and to treat the viral diseases, human immunodeficiency virus (HIV) and hepatitis-C. The Company’s other wholly owned subsidiary Designer Diagnostics, Inc. (Designer Diagnostics) is engaged in marketing diagnostic test kits that are used for the rapid identification of infectious human diseases, such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Midterm goal Nutra Pharma Corp’s midterm strategy for the past three years has been to license Nutra Pharma Corp’s AMN, MS and HIV technologies in Nutra Pharma Corp’s attempt to bring these technologies to market within 5 years. Should Nutra Pharma Corp. obtain adequate financing, Nutra Pharma Corp’s midterm strategy remains the same— to accomplish these midterm goals in the next two years of that 5 year period. Long-term goal Nutra Pharma Corp’s long-term goal is the use of drugs developed by ReceptoPharm and future affiliates in the field of neurological diseases, infectious diseases and autoimmune disorders. Due to Nutra Pharma Corp’s limited financial and operational resources, this goal will require Nutra Pharma Corp. to establish strategic partners or alliances with pharmaceutical companies, academic institutions, biotechnology companies, and clinical diagnostic laboratories, which will: (a) complement Nutra Pharma Corp’s research and development efforts; (b) reduce the risks associated with undertaking the entire process of drug development and marketing; and (c) generate licensing based revenue streams. Read full article at New Pain Treatment Triumphs Morphine (OTC:NPHC) | [...]

]]>